RxDoctor Payments Data

Rafael Hernandez Lora, MD

Internal Medicine · Miramar, FLNPI 1689914814

Payments from drug & device makers

$587in general payments, 2019–2025

Across 27 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$203
  • Exact Sciences$129
  • AstraZeneca$94
  • Abbott$41
  • Amgen$28
  • Boehringer Ingelheim$23
  • plus $69 from 4 others

What the payments were for

  • Food & beverage$587100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$587 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$480,768
Medicare patients
337
Services billed
4,320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$120,319
BiktarvyBictegrav/Emtricit/Tenofov Ala13$48,472
TradjentaLinagliptin12$15,688
OzempicSemaglutide15$14,728
FarxigaDapagliflozin Propanediol18$12,570
MyrbetriqMirabegron13$12,242
XareltoRivaroxaban12$9,108
NamzaricMemantine Hcl/Donepezil Hcl11$6,157
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,567
Spiriva HandihalerTiotropium Bromide11$5,472
CombiganBrimonidine Tartrate/Timolol19$4,534
Memantine Hcl57$2,701
Cinacalcet Hcl18$2,657
Olanzapine28$2,228
Celecoxib37$2,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$120,319136 claims
Boehringer IngelheimTradjenta$23$15,68812 claims
Novo NordiskOzempic$203$14,72815 claims
AstraZenecaFarxiga$94$12,57018 claims
Astellas Pharma US IncMyrbetriq$16$12,24213 claims
Lilly USA, LLCOlanzapine$18$2,22828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miramar

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →